dearMoon PROJECT

The first civilian mission to the Moon is planned to take place in 2023. The rocket developed by Elon Musk’s SpaceX will make a week-long journey to the Moon and back. In 2018,Japanese entrepreneur Yusaku Maezawa purchased all the seats aboard this rocket.Wishing to give as many talented individuals as possible the opportunity to go,he announced in March 2021 his plans to choose 8 crew members from across the world.

A Japanese company that focuses on aerospace technologies. I love their rocket designs. I can’t wait to start producing spaceships of my own one day. I want to see humanity become completely self-sufficient in technology. It’s vital for the preservation of our species.

I believe the future of humanity is in space travel. Mars is the first step of an exciting future! Who knows where we might go next… Perhaps we’ll be going to distant solar systems in a few centuries.

https://dearmoon.earth/

Lucy Therapeutics – Female-founded biotech company Lucy Therapeutics

We are filled with curiosity as we seek to identify what signals cause healthy cells to become disordered or dysfunctional. Mitochondria have caught our attention as potentially key drivers of complex conditions, particularly disorders of the central nervous and cardiovascular systems. We are investing tireless effort to unlock the complexities and explore the interrelated processes that lead to mitochondrial dysfunction. Our ultimate ambition lies in arresting diseases and finding a path back to health.

https://www.lucytherapeutics.com/

My Aging Test

MyAgingTests.com

A website that provides information on aging and longevity research. The reversal of epigenetic aging clocks promises to lower the risk of multiple chronic diseases and preserve the immune system.

MyAgingTests.comis a community branch of the Clock Foundation. This non-profit, which is longevity-oriented, is based in Los Angeles.

The Epigenetic Clock Development Foundation (“Clock Foundation”), a UCLA spin-out, is working to speed up the availability of treatments that extend life expectancy and health. Our focus is on adaptive clinical trials and epigenetic aging clocks. We will develop and identify key enabling technologies, identify promising teams, and make them available for our partners including researchers, physicians/clinics and drug development companies.

The epigenetic aging clocks , which are strong indicators for biological age, can be reversed to reduce the risk of many chronic diseases and preserve the immune system. Preclinical and human studies have shown that epigenetic clocks can be used as a surrogate endpoint in anti-aging clinical trials.

Our goal is to lower the cost of epigenetic testing and to perform mechanistic studies. We also aim to develop more powerful biomarkers to predict healthspan and longevity (including a fast, safe, and effective testing regimen for humans, model organisms and companion animals). We will test and analyze several biomarkers that indicate aging, including markers of immunosenescence and epigenetic aging clocks. The work will lead to the qualification of several biomarkers for aging as surrogate trial ends.